WW de Herder
- Neurology top 5%
- Neuroblastoma Research and Treatments 4
-
- Pituitary Gland Disorders and Treatments 5
- Growth Hormone and Insulin-like Growth Factors 3
- Epidemiology top 5%
- Neuroendocrine Tumor Research Advances 7
- Oncology top 10%
- Lung Cancer Research Studies 4
- Pancreatic and Hepatic Oncology Research 3
-
- Adrenal and Paraganglionic Tumors 2
-
- Cancer, Hypoxia, and Metabolism 1
- Co-authors
- AJ van der LelyLarry K. KvolsBertram WiedenmannEugene A. WolteringPhilippe RuszniewskiGuido RindiG. Delle FaveMartyn Caplin
- Partner nations
- NetherlandsGermanyUnited States
In The Last Decade
WW de Herder
13 papers receiving 819 citations
Peers
Comparison fields: 5 of 51
- Neurology 423
- Endocrinology, Diabetes and Metabolism 343
- Epidemiology 540
- Oncology 418
- Surgery 143
Countries citing papers authored by WW de Herder
This map shows the geographic impact of WW de Herder's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by WW de Herder with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites WW de Herder more than expected).
Fields of papers citing papers by WW de Herder
This network shows the impact of papers produced by WW de Herder. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by WW de Herder. The network helps show where WW de Herder may publish in the future.
Co-authorship network
The 25 scholars most cited alongside WW de Herder, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | A randomized controlled study comparing treatment of gastro-entero-pancreatic neuroendocrine tumors (GEPNET) with 177Lu-DOTATATE alone and in combination with capecitabine | 2018 | 3 |
| 2 | 2017 | 10 | |
| 3 | Efficacy, Safety and Pharmacokinetic Results from a Phase II Study of Pasireotide (SOM230) in the Treatment of Patients with Metastatic NETs Refractory or Resistant to Octreotide LAR | 2010 | 5 |
| 4 | 2007 | 32 | |
| 5 | 2007 | 10 | |
| 6 | 2006 | 48 | |
| 7 | 2005 | 179 | |
| 8 | 2005 | 11 | |
| 9 | 2004 | 415 | |
| 10 | The novel somatostatin analog SOM230 has a broad spectrum of inhibitory action on hormone release by human somatotroph, corticotroph and PRL-secreting pituitary adenomas in vitro | 2003 | 2 |
| 11 | 2002 | 20 | |
| 12 | 2002 | 12 | |
| 13 | 1998 | 97 |
About WW de Herder
WW de Herder is a scholar working on Endocrinology, Diabetes and Metabolism, Neurology and Oncology, having authored 13 papers that have together received 844 indexed citations. Recurring topics across this work include Neuroendocrine Tumor Research Advances (7 papers), Pituitary Gland Disorders and Treatments (5 papers), Neuroblastoma Research and Treatments (4 papers), Lung Cancer Research Studies (4 papers), Pancreatic and Hepatic Oncology Research (3 papers), Growth Hormone and Insulin-like Growth Factors (3 papers), Adrenal and Paraganglionic Tumors (2 papers) and Cancer, Hypoxia, and Metabolism (1 paper). The work is most often cited by research in Neurology (423 citations), Endocrinology, Diabetes and Metabolism (343 citations) and Epidemiology (540 citations). WW de Herder has collaborated with scholars based in Netherlands, Germany and United States. Frequent co-authors include AJ van der Lely, Larry K. Kvols, Bertram Wiedenmann, Eugene A. Woltering, Philippe Ruszniewski, Guido Rindi, G. Delle Fave, Martyn Caplin, K. Öberg and J. A. M. J. L. Janssen. Their work appears in journals such as The Lancet, Journal of Clinical Oncology and Annals of Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.